DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Cwm LLC

Cwm LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 140,337 shares of the medical device company’s stock after selling 5,529 shares during the period. Cwm LLC’s holdings in DexCom were worth $15,911,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. International Assets Investment Management LLC purchased a new stake in DexCom in the 4th quarter worth approximately $1,986,000. Prime Capital Investment Advisors LLC lifted its position in DexCom by 150.4% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 7,877 shares of the medical device company’s stock worth $977,000 after buying an additional 4,731 shares during the period. Silvant Capital Management LLC boosted its stake in DexCom by 1.7% in the 4th quarter. Silvant Capital Management LLC now owns 261,018 shares of the medical device company’s stock worth $32,390,000 after buying an additional 4,397 shares during the last quarter. Raub Brock Capital Management LP acquired a new stake in DexCom in the 4th quarter worth about $292,000. Finally, Valley National Advisers Inc. grew its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Down 7.9 %

Shares of NASDAQ DXCM traded down $5.93 during trading on Wednesday, reaching $69.32. 10,004,696 shares of the stock were exchanged, compared to its average volume of 3,724,563. The company has a market capitalization of $27.57 billion, a price-to-earnings ratio of 45.48, a price-to-earnings-growth ratio of 2.18 and a beta of 1.16. The business’s 50-day moving average price is $107.19 and its 200 day moving average price is $121.03. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.34 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jereme M. Sylvain sold 745 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the sale, the chief financial officer now directly owns 84,948 shares in the company, valued at $9,773,267.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,135 shares of company stock worth $446,797. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DXCM. Raymond James raised their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Redburn Atlantic began coverage on shares of DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target on the stock. Royal Bank of Canada lowered their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Finally, Oppenheimer reduced their target price on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $111.63.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.